Eli Lilly (LLY) Stock Analysis

September 7, 2026

This is a peer-relative look at Eli Lilly (LLY): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.

Company Profile

Company profile fields for Eli Lilly (LLY)
Profile Item	LLY
Name	Eli Lilly and Company
Country/Region	United States
GICS Sector	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals
GICS Sub-Industry	Pharmaceuticals
Market Capitalization	1,024.93 billion USD
Currency	USD
Exchange	NYSE
Listing Date	June 1, 1972
Security Type	Common Stock

Price Performance

Cumulative Growth

LLY

GSPC

Eli Lilly (LLY) vs. S&P 500 (GSPC): Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Eli Lilly (LLY) and S&P 500 (GSPC). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Eli Lilly (LLY) and S&P 500 (GSPC). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Eli Lilly (LLY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: LLY	Industry group median
Total Return (1Y)	55.69%	48.26%
Total Return (3Y, Annualized)	28.18%	12.46%
Total Return (5Y, Annualized)	35.89%	-4.88%

Risk Profile

Drawdown History

LLY

GSPC

Eli Lilly (LLY) vs. S&P 500 (GSPC): Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Eli Lilly (LLY) and S&P 500 (GSPC). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Eli Lilly (LLY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: LLY	Industry group median
Volatility (1Y, Annualized)	35.83%	67.21%
Beta (5Y)	0.45	0.93
Max Drawdown (5Y)	-34.48%	-82.64%

Risk-Adjusted Performance

Risk-Return Positioning

Each dot is a stock plotted by 1-year volatility (risk) and 1-year return. LLY is highlighted; the dashed line is the Capital Allocation Line from the risk-free rate through the industry median — dots above it are stronger on a risk-adjusted basis.

Risk-Adjusted Metrics

Eli Lilly (LLY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: LLY	Industry group median
Sharpe Ratio (1Y)	1.44	0.78
Sortino Ratio (1Y)	2.46	1.30

Profitability

ROE (TTM)

Eli Lilly (LLY) posts ROE of 102.29%, in the upper peer quartile. That suggests the company earns more from each dollar of shareholders’ equity than most industry peers, a useful capital-efficiency signal.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

102.29%

Group distribution

LLY: 102.29%
Max: 102.29%
Q3: 3.16%
Median: -32.34%
Q1: -64.79%
Min: -157.61%

Largest peers

LLY: 102.29%
AMGN: 91.47%
NVS: 30.35%
JNJ: 25.74%
AZN: 21.97%
MRK: 6.96%
ABBV: --

Where Eli Lilly (LLY) stands on ROE within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Net Margin (TTM)

Eli Lilly (LLY) keeps 33.53% of revenue as net profit on net margin, above the industry benchmark range. That is unusually strong bottom-line conversion, though tax effects, asset sales, or other one-off gains should be checked before treating it as durable.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.53%

Group distribution

LLY: 33.53%
Max: 12.02%
Q3: 2.44%
Median: 0.00%
Q1: -4.89%
Min: -13.51%

Largest peers

LLY: 33.53%
AMGN: 22.95%
NVS: 22.50%
JNJ: 21.48%
AZN: 17.02%
ABBV: 9.80%
MRK: 4.77%

Where Eli Lilly (LLY) stands on net margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Operating Margin (TTM)

Eli Lilly (LLY) turns 54.22% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

54.22%

Group distribution

Max: 76.04%
LLY: 54.22%
Q3: 10.45%
Median: 0.00%
Q1: -120.32%
Min: -308.66%

Largest peers

LLY: 54.22%
ABBV: 40.04%
AMGN: 35.55%
NVS: 34.62%
JNJ: 29.19%
AZN: 23.46%
MRK: -0.24%

Where Eli Lilly (LLY) stands on operating margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Profitability Metrics

Eli Lilly (LLY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: LLY	Industry group median
ROE (TTM)	102.29%	-32.34%
ROA (TTM)	20.36%	-14.69%
Net Margin (TTM)	33.53%	0.00%
Operating Margin (TTM)	54.22%	0.00%
Gross Margin (TTM)	83.40%	33.96%

Growth

Revenue Growth

Eli Lilly (LLY) grew revenue 44.70%, roughly around the peer group's normal range. Top-line momentum looks broadly typical for the industry.

Eli Lilly (LLY): Revenue Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

EPS Growth

Eli Lilly (LLY) grew earnings per share 95.99%, in the upper peer quartile. Per-share profits are compounding faster than at most industry peers.

Eli Lilly (LLY): EPS Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

Growth Metrics

Eli Lilly (LLY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: LLY	Industry group median
Revenue Growth (YoY)	44.70%	10.61%
Revenue Growth (3Y CAGR)	31.69%	10.96%
EPS Growth (YoY)	95.99%	3.16%
EPS Growth (3Y CAGR)	51.71%	3.62%

Financial Strength

Current Ratio (MRQ)

Eli Lilly (LLY) has current ratio of 1.36, in the tighter-liquidity quartile for its industry. The short-term cushion is thinner than most peers carry, even if the absolute comfort level still depends on the business model.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.36

Group distribution

Max: 26.10
Q3: 12.34
Median: 5.72
Q1: 2.80
LLY: 1.36
Min: 0.10

Largest peers

AMGN: 1.37
LLY: 1.36
MRK: 1.32
JNJ: 1.09
AZN: 0.89
NVS: 0.86
ABBV: 0.81

Where Eli Lilly (LLY) stands on current ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Debt / Equity (MRQ)

Eli Lilly (LLY) has debt-to-equity ratio of 1.62, above the industry benchmark range. Debt sits unusually high against shareholders’ equity, leaving the balance sheet more exposed to rate, refinancing, or earnings shocks.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.62

Group distribution

LLY: 1.62
Max: 1.56
Q3: 0.64
Median: 0.14
Q1: 0.02
Min: 0.00

Largest peers

AMGN: 4.90
LLY: 1.62
MRK: 1.28
NVS: 1.17
AZN: 0.64
JNJ: 0.58
ABBV: --

Where Eli Lilly (LLY) stands on debt-to-equity ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Financial Strength Metrics

Eli Lilly (LLY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: LLY	Industry group median
Current Ratio (MRQ)	1.36	5.72
Debt / Equity (MRQ)	1.62	0.14
Net Debt / EBITDA	1.10	1.15

Dividends

Dividend Yield (TTM)

Eli Lilly (LLY) has dividend yield of 0.56%, above the entire industry range. That headline income is large, but yields this far above peers often come from a falling share price or an at-risk payout, so dividend safety matters more than the percentage itself.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.56%

Group distribution

LLY: 0.56%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

NVS: 2.86%
ABBV: 2.62%
AMGN: 2.21%
MRK: 2.18%
AZN: 1.96%
JNJ: 1.88%
LLY: 0.56%

Where Eli Lilly (LLY) stands on dividend yield within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Payout Ratio (TTM)

Eli Lilly (LLY) has payout ratio of 21.69%, above the peer distribution for its industry. The dividend consumes more reported earnings than peers normally do, leaving unusually thin earnings cover.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.69%

Group distribution

LLY: 21.69%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

MRK: 268.80%
ABBV: 190.40%
NVS: 71.60%
AMGN: 60.87%
JNJ: 60.79%
AZN: 47.41%
LLY: 21.69%

Where Eli Lilly (LLY) stands on payout ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Metrics

Eli Lilly (LLY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: LLY	Industry group median
Dividend Yield (TTM)	0.56%	0.00%
Dividend Payout Ratio (TTM)	21.69%	0.00%

Valuation

P/E Ratio (TTM)

Eli Lilly (LLY) trades at P/E ratio of 38.61, near the industry’s usual earnings multiple. The stock is not showing a clear peer discount or premium on trailing earnings.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.61

Group distribution

Max: 83.73
Q3: 44.68
LLY: 38.61
Median: 28.50
Q1: 15.51
Min: 0.14

Largest peers

MRK: 120.26
ABBV: 72.45
LLY: 38.61
JNJ: 31.97
AMGN: 27.17
AZN: 24.32
NVS: 24.17

Where Eli Lilly (LLY) stands on P/E ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/S Ratio (TTM)

Eli Lilly (LLY) trades at 12.86 on P/S ratio, roughly in the peer group’s normal range. The market is not making a strong cheap-or-rich statement about its revenue base.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.86

Group distribution

Max: 65.27
Q3: 29.50
LLY: 12.86
Median: 7.31
Q1: 3.49
Min: 0.01

Largest peers

LLY: 12.86
ABBV: 7.04
JNJ: 6.77
AMGN: 6.21
MRK: 5.57
NVS: 5.36
AZN: 4.11

Where Eli Lilly (LLY) stands on P/S ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/B Ratio (MRQ)

Eli Lilly (LLY) trades at 30.24 on P/B ratio, above the industry benchmark range. Investors are putting an unusually rich price on each dollar of book equity relative to peers.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.24

Group distribution

LLY: 30.24
Max: 15.46
Q3: 7.32
Median: 4.02
Q1: 1.90
Min: -5.81

Largest peers

LLY: 30.24
AMGN: 20.22
MRK: 8.85
JNJ: 7.80
NVS: 7.32
AZN: 5.02
ABBV: -76.35

Where Eli Lilly (LLY) stands on P/B ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Valuation Metrics

Eli Lilly (LLY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: LLY	Industry group median
P/E Ratio (TTM)	38.61	28.50
P/S Ratio (TTM)	12.86	7.31
P/B Ratio (MRQ)	30.24	4.02
Free Cash Flow Yield (TTM)	1.08%	-1.84%